This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. | Classification codes — C32 (Malignant neoplasm of larynx) |
| B. | Synonyms — Laryngeal cancer, glottic cancer, supraglottic cancer, subglottic cancer, laryngeal squamous cell carcinoma |
| C. | Adult onset — Very high (mainly in their mid-50s to 70s; overwhelmingly more common in men who smoke and drink) |
| 1. | History — Invention of the laryngoscope (Garcia 1854); history of laryngectomy; elucidation of the epidemiology of smoking and laryngeal cancer |
| 2. | Causes — Smoking (most important), alcohol (synergistic with smoking), occupational exposure (asbestos, nickel, sulfuric acid fumes), HPV |
| 3. | Genetics — TP53 (~50%), CDKN2A, EGFR overexpression/amplification, PIK3CA, CCND1; prognostic association of EGFR |
| 4. | Epidemiology — The most common head and neck cancer worldwide; about 1,200 cases per year in Korea; male-to-female ratio 5–10:1 |
| 5. | Pathophysiology — Smoking carcinogens → squamous metaplasia → dysplasia → carcinoma in situ → invasive carcinoma; glottic vs supraglottic differences |
| 6. | Symptoms — Hoarseness (altered voice; early symptom of glottic cancer), dysphagia, otalgia, dyspnea, neck mass |
| 7. | Signs — Vocal cord mass/ulcer on laryngoscopy, vocal cord fixation, inspiratory stridor, cervical lymphadenopathy, EGFR expression |
| 8. | Screening — No standard screening; laryngoscopic evaluation recommended for high-risk smokers with hoarseness persisting for more than 2 weeks |
| 9. | Diagnosis — Flexible nasopharyngolaryngoscopy, direct laryngoscopy under general anesthesia + biopsy, CT/MRI, PET-CT, AJCC TNM 8th edition |
| 10. | Treatment — Larynx-preserving surgery (laser/partial laryngectomy); total laryngectomy; cisplatin + radiation (CCRT); cetuximab |
| 11. | Prognosis — Glottic cancer T1 5-year survival about 90%; supraglottic cancer poorer; overall 5-year survival about 60%; EGFR associated with poor prognosis |
| 12. | Prevention — Smoking cessation (most effective), moderation of alcohol intake, prevention of occupational exposure, HPV vaccination, early symptom detection |
| 13. | References — NCCN Head and Neck Cancers, VA Laryngeal Cancer Study, RTOG 91-11, EXTREME, and others (10 in total) |
Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date
| Category | Details |
|---|---|
| ICD-10 code | C32 — Malignant neoplasm of larynx |
| Subcodes | C32.0 glottis (including true vocal cord), C32.1 supraglottis (epiglottis, arytenoid cartilage, laryngeal ventricle, etc.), C32.2 subglottis, C32.3 malignant neoplasm of laryngeal cartilage, C32.8 overlapping lesion, C32.9 unspecified |
| Special Copayment Reduction code | V193 |
| Main histological types | Squamous cell carcinoma about 95–98%; adenocarcinoma, neuroendocrine tumor (carcinoid), chondrosarcoma (rare) |
Laryngeal cancer, glottic cancer (true vocal cord cancer), supraglottic cancer, subglottic cancer, laryngeal squamous cell carcinoma (LSCC), laryngeal malignancy, laryngeal carcinoma. It is included as a subcategory of head and neck squamous cell carcinoma (HNSCC). Differences in clinical characteristics by the location of laryngeal cancer are important for treatment decisions.
Laryngeal cancer is a disease with a very high frequency of adult onset, with a median age at diagnosis of about 65 years. It occurs 5–10 times more often in men than in women, which is related to sex differences in smoking and drinking. Onset before age 40 is rare. With the rising smoking rate among women, laryngeal cancer in women is increasing.
The history of laryngeal cancer is closely linked to the development of instruments for observing the larynx. In 1854, the Spanish singing teacher Manuel Garcia first succeeded in directly observing his own vocal cords using a dental mirror, and this method became the origin of clinical laryngoscopy. In 1858, Czermak applied Garcia's method medically and introduced indirect laryngoscopy into clinical practice. In 1913, Jackson developed the direct laryngoscope, making tissue biopsy possible.
In the history of treatment, total laryngectomy was first performed by Billroth in 1873, making curative surgical treatment possible. As the importance of larynx preservation subsequently came to the fore, Alonso introduced partial laryngectomy in 1948, and radiotherapy alone or postoperative combined radiotherapy was established in the 1960s–1970s. In 1991, the Veterans Affairs Laryngeal Cancer Study Group (VA Laryngeal Cancer Study) demonstrated that in advanced laryngeal cancer, induction chemotherapy (cisplatin + 5-FU) + radiation achieved survival equivalent to immediate total laryngectomy while preserving the larynx. This landmark result became the foundation of the larynx-preservation treatment paradigm. In 2003, the RTOG 91-11 study demonstrated that concurrent chemoradiotherapy (CCRT, cisplatin + radiation) achieved a better larynx preservation rate than induction chemotherapy + radiation or radiation alone, establishing CCRT as the standard for T3–T4 laryngeal cancer.
The association between EGFR and laryngeal cancer prognosis has been studied since the 1990s, and in 2007 studies such as PMC2075924 systematically reported the poor prognosis of EGFR-positive laryngeal cancer. Cetuximab (EGFR inhibitor) became the first targeted agent after the EXTREME trial (2008) showed improved OS in recurrent/metastatic head and neck cancer when combined with platinum-based chemotherapy. In 2016, KEYNOTE-012 began to show the efficacy of pembrolizumab in PD-L1-positive head and neck cancer, and in 2019, KEYNOTE-048 added pembrolizumab alone or combined with platinum + 5-FU as first-line standard treatment for recurrent/metastatic head and neck cancer.
Smoking is the strongest and most consistent risk factor for laryngeal cancer; smokers have about 10–20 times the risk of nonsmokers. The risk rises in proportion to daily amount and duration of smoking, and decreases gradually after quitting, but it takes 10–20 years to return to the level of nonsmokers. Alcohol is an independent risk factor, but combined with smoking it has a synergistic effect that greatly increases the risk. The alcohol-related risk is particularly prominent in supraglottic cancer.
Asbestos exposure has been reported to increase the risk of laryngeal cancer about 2-fold (IARC Group 1 carcinogen). Associations have also been reported for exposure to strong acid fumes (sulfuric acid), wood dust, nickel, formaldehyde, and petroleum-related substances. HPV (especially HPV16) is detected in a portion (about 10–20%) of laryngeal cancers, but less frequently than in oropharyngeal cancer and with less clear clinical significance. GERD (gastroesophageal reflux disease) has also been reported as a risk factor for subglottic and glottic cancer.
The molecular genetics of laryngeal squamous cell carcinoma (LSCC) have much in common with head and neck squamous cell carcinoma (HNSCC). The most frequent somatic alterations are TP53 (about 50%), CDKN2A (p16) loss (about 50–60%), CCND1 amplification (cyclin D1, cell-cycle promotion), and PIK3CA variants (about 10–15%). EGFR (epidermal growth factor receptor) is overexpressed in about 70–90% of laryngeal cancers, and EGFR positivity is associated with a poor prognosis (5-year survival 25% vs 81% for EGFR-negative). EGFR gene amplification is also observed in some cases. Cetuximab (EGFR inhibitor) is used in treatment, but EGFR expression itself does not predict response to cetuximab.
HPV-positive laryngeal cancer is infrequent (about 10–20%), and a prognostic advantage like that of HPV-positive oropharyngeal cancer has not been clearly demonstrated. PD-L1 expression (CPS ≥1 or ≥20) is used as a biomarker to predict response to pembrolizumab. MSI-H is rare in head and neck squamous cell carcinoma (about 1–2%). NOTCH1, FAT1, KMT2D, NSD1, PIK3CA, and HRAS variants are also included in the molecular subtyping of HNSCC.
Laryngeal cancer is the most common malignancy among head and neck cancers, accounting for about 25–30% of head and neck cancers worldwide. Worldwide there are about 170,000–180,000 new cases (GLOBOCAN 2020) and about 90,000 deaths per year. Incidence in men is 5–10 times higher than in women; in high-income countries incidence is declining with reduced smoking, while it is increasing in some developing countries.
In Korea, about 1,200–1,500 cases of laryngeal cancer occur per year, with incidence much higher in men than in women (about 9:1). With the recent decline in the smoking rate among Korean men, the incidence of laryngeal cancer is also gradually decreasing. Distribution by site: glottic cancer (including the true vocal cords) about 60–65%, supraglottic cancer about 30–35%, subglottic cancer about 1–5%. Glottic cancer causes hoarseness early, allowing early detection, whereas supraglottic cancer causes symptoms late and is often diagnosed at an advanced stage.
The pathogenesis of laryngeal cancer is understood as a multistep carcinogenic process of DNA damage to the laryngeal squamous epithelium → squamous metaplasia → dysplasia → carcinoma in situ → invasive squamous cell carcinoma caused by carcinogens in tobacco smoke such as polycyclic aromatic hydrocarbons (PAH), nitrosamines, and benzopyrene. Tobacco carcinogens form DNA adducts, and if these are not repaired, variants accumulate in tumor suppressor genes such as TP53 and CDKN2A. Alcohol acts synergistically with smoking through mechanisms such as DNA cross-link formation by acetaldehyde produced when ethanol is oxidized, abnormal DNA methylation via folate deficiency, and enhanced dissolution of nicotine combustion products.
There are differences in pathogenesis and clinical characteristics between the glottis and supraglottis. The glottis has very few lymphatics, so lymph node metastasis occurs late, and even small tumors cause hoarseness early, favoring early detection. In contrast, the supraglottis has a rich lymphatic network, and cervical lymph node metastasis is already present in about 50% at diagnosis. EGFR overexpression promotes cell proliferation through constitutive activation of the RAS-MAPK pathway and contributes to radioresistance.
Dysphonia (hoarseness) is the earliest symptom of glottic cancer; even a small lesion on the true vocal cord alters vocal cord vibration and causes a hoarse voice. Smokers and drinkers with hoarseness persisting for more than 2 weeks must undergo laryngoscopic evaluation. As the disease progresses, dysphagia, otalgia (ear pain) (vagal reflex), dyspnea, and stridor appear.
Supraglottic cancer initially causes only nonspecific symptoms such as a foreign body sensation in the throat or throat discomfort, making early detection difficult. Dysphagia, otalgia, weight loss, and a neck mass (lymph node metastasis, present in about 50% at diagnosis) are the main symptoms. Subglottic cancer is rare, but in advanced laryngeal cancer symptoms of airway obstruction (dyspnea, inspiratory stridor) appear.
Flexible nasopharyngolaryngoscopy or indirect laryngoscopy reveals a vocal cord mass/ulcer, vocal cord fixation (due to tumor infiltration or vocal cord nerve palsy), and vocal cord edema. Detailed observation and biopsy are performed by direct laryngoscopy. Inspiratory stridor suggests airway obstruction and may require emergency airway management. Cervical lymphadenopathy is more common in supraglottic and subglottic cancers, mainly involving ipsilateral level II–III lymph nodes. Serum EGFR expression and PD-L1 (CPS) are molecular markers referred to in treatment selection.
There is no national standard screening test for laryngeal cancer. However, high-risk individuals (smokers and drinkers, especially smokers of 20 pack-years or more) with hoarseness, dysphagia, or a foreign body sensation persisting for more than 2 weeks are advised to visit an otolaryngologist early for laryngoscopic evaluation. For people with high-risk occupational exposure (asbestos, nickel refining workers), including an otolaryngologic examination in regular health checkups is recommended. Smoking cessation and moderation of alcohol intake are the most effective means of primary prevention.
Flexible nasopharyngolaryngoscopy is used for initial evaluation, assessing lesion location, size, and vocal cord mobility. Direct laryngoscopy (direct laryngoscopy under general anesthesia) is used for detailed lesion evaluation and biopsy and, if needed, laser resection. Stroboscopy (evaluation of vocal cord vibration) is used as an adjunct in T1 glottic cancer.
Neck CT (dynamic contrast-enhanced) evaluates tumor extent, subglottic extension, cartilage invasion, and cervical lymph node metastasis. MRI is superior to CT for evaluating soft tissue and perineural invasion and tumor infiltration into cartilage. PET-CT is used to evaluate distant metastasis and cervical lymph nodes. AJCC TNM 8th edition staging: separate T classification systems are used for the glottis, supraglottis, and subglottis. Glottic cancer T1: one or both vocal cords, normal vocal cord mobility; T2: supraglottic or subglottic extension or impaired vocal cord mobility; T3: vocal cord fixation or intracartilaginous infiltration; T4: extracartilaginous infiltration or distant extension.
As first-line treatment for T1 glottic cancer, CO2 laser endoscopic resection (transoral laser microsurgery, TLM) and radiotherapy (60–66 Gy) achieve equivalent local control rates, with radiation somewhat favored for voice preservation. For T2 glottic cancer, radiation alone or TLM is used. For T1–T2 supraglottic cancer, radiation alone or supraglottic partial laryngectomy is performed.
For T3 laryngeal cancer in which larynx preservation is possible, cisplatin + radiation concurrent chemoradiotherapy (CCRT, based on RTOG 91-11) is standard. Cisplatin 100 mg/m² is given every 3 weeks concurrently with irradiation. For T4a (cartilage infiltration or invasion of extralaryngeal structures), total laryngectomy + neck dissection + adjuvant radiation (± chemotherapy) is performed. After total laryngectomy, a permanent tracheostomy opening is required, and communication is partly restored with a voice aid (tracheoesophageal voice prosthesis, TEP) or esophageal speech.
First-line standard systemic treatment for recurrent/metastatic head and neck cancer (including laryngeal cancer) is pembrolizumab alone (PD-L1 CPS ≥1) or pembrolizumab + cisplatin + 5-FU (KEYNOTE-048). The EXTREME regimen (cisplatin + 5-FU + cetuximab) is also a first-line option. Cetuximab combined with radiotherapy is effective in locally advanced head and neck cancer (Bonner 2006) but is not superior to cisplatin + radiation.
The prognosis of laryngeal cancer differs greatly by primary site (glottic vs supraglottic) and stage. In T1 glottic cancer, the 5-year local control and survival rates are very favorable at 85–95%. T2 glottic cancer: 5-year survival about 65–80%. Supraglottic cancer has a higher frequency of lymph node metastasis at diagnosis and a poorer prognosis than glottic cancer of the same stage (T3 5-year survival about 45–60%). T4/metastatic: 5-year survival 20–40%; poor prognosis in metastatic disease (median OS 10–14 months). Overall 5-year survival for laryngeal cancer is about 60%. EGFR-positive laryngeal cancer has markedly lower 5-year survival than EGFR-negative (about 25% vs 81%, PMC2075924). Vocal cord fixation (T3 or higher) and cervical lymph node metastasis (N2 or higher) are poor prognostic factors.
Smoking cessation: the most effective means of preventing laryngeal cancer. The risk approaches that of nonsmokers 15–20 years after quitting. Smoking cessation aids (nicotine replacement therapy, varenicline, bupropion), behavioral therapy, and cessation counseling are used. Moderation of alcohol intake: limit drinking to 2 drinks a day or less (1 for women) or abstain. Prevention of occupational exposure: block asbestos exposure (personal protective equipment, ventilation), manage exposure to strong acid fumes. HPV vaccination: as primary prevention of HPV-related head and neck cancers overall, the possibility that the 9-valent HPV vaccine contributes to preventing HPV-related head and neck cancer is being studied. Early symptom recognition: public education is needed so that smokers and drinkers with hoarseness persisting for more than 2 weeks promptly see a specialist. GERD treatment (PPI or lifestyle modification) may also help.